Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies

BACKGROUND: Late or chronic active antibody-mediated rejection (AMR) associated with de novo donor-specific antibodies (dnDSA) after renal transplantation is a great clinical challenge because it is often resistant to conventional therapies. Daratumumab, an anti-CD38 monoclonal antibody that can dep...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Lan, Guo, Zhiliang, Zhao, Daqiang, Sa, Rula, Zhao, Guangyuan, Guo, Hui, Chen, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875042/
https://www.ncbi.nlm.nih.gov/pubmed/36713391
http://dx.doi.org/10.3389/fimmu.2022.1087597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875042/
https://www.ncbi.nlm.nih.gov/pubmed/36713391
http://dx.doi.org/10.3389/fimmu.2022.1087597

Ejemplares similares